Available Technologies
# of Displayed Technologies: 10 / 10
Applied Category Filter (Click To Remove): Small Molecules
Selective Estrogen Receptor Beta Agonists
TS-062680 — According to the American Cancer Society, breast cancer is the most common cancer for women in the US, except for skin cancer. It comprised about 30% of all new female cancers each year. While breast cancer death rates have decreased over the last several decades, it remains the second leading cause…
- College: College of Pharmacy
- Inventors: Bennett, Chad; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Dual Androgen Receptor/AKR1C3 Inhibitors for Prostate Cancer
TS-062605 — The Need:
Castration-resistant prostate cancer (CRPC) poses a significant challenge in oncology, with existing therapies often leading to resistance and disease progression. Key drivers of resistance include the androgen receptor (AR) and aldo-keto reductase family 1 member C3 (AKR1C3). Novel treat…
- College: College of Pharmacy
- Inventors: Li, Pui-Kai "Tom"; Cheng, Xiaolin; Kong, Xiaotian; Xing, Enming
- Licensing Officer: Schworer, Adam
Novel Natural Product Derivatives Targeting Chronic Diseases
TS-050220 — Novel natural products and derivatives thereof that exhibit potent in vitro and in vivo activity
The Need
Metabolic disorders such as type 2 diabetes are a major health concern that have impacted hundreds of millions of adults worldwide. Current pharmaceutical therapies for type 2 diabetes have been associated with adverse reactions including weight gain and increased risk of infection, liver …
- College: College of Pharmacy
- Inventors: Carcache de Blanco, Esperanza; Anaya Eugenio, Gerardo David; Eggers, Nicole
- Licensing Officer: He, Panqing
Novel epipolythiodioxopiperazine alkaloid natural product derivatives for the treatment of cancer and other diseases
TS-047118 —
Analogues of verticillin with significantly improved drug-like properties, including increased solubility, absorption, and stability, while maintaining similar anticancer potency as the verticillin parent compounds.
Verticillins, which are epipolythiodioxopiperazine (ETP) alkaloids, have shown promising anticancer qualities; these fungal metabolites have exhibited high potency against a variety of tumor cell types, with IC50 values typically in the 10-500 nanomolar range. However, these compounds suffer from …
- College: College of Pharmacy
- Inventors: Fuchs, James; Huntsman, Andrew
- Licensing Officer: He, Panqing
Novel Small-Molecule Integrin-linked Kinase/Phosphoinositide-dependent Protein Kinase-2 Inhibitors
TS-037647 — A novel set of molecules that inhibit integrin-linked kinase in order to suppress tumor cell growth and metastasis.
The Akt signaling pathway is responsible for apoptosis, cell proliferation, and metabolism. In tumor cells, this pathway is up-regulated and aids in promoting cancer cell survival. Complete activation of Akt pathway requires phosphorylation at two amino-acid residues, which are phosporylated by se…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Kulp, Samuel; Lee, Su-Lin
- Licensing Officer: Taysavang, Panya
Estrogen Receptor Beta Agonist Compounds
TS-015086 — Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.
There is a large emphasis on the need for novel and more effective cancer therapeutics, since there were nearly 600,000 cancer deaths in the United States in 2016 alone. One method for therapy of prostate, breast, and colon cancer that has been gaining traction is the targeting of estrogen recepto…
- College: College of Pharmacy
- Inventors: Tjarks, Werner; Bartunek, Petr; Sedlak, David
- Licensing Officer: Taysavang, Panya
Small Molecule AR-Ablative Agents
TS-014842 — A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.
Hormone-refractory prostate cancer is incurable, and patients with this disease have few treatment options. Dysregulation of the androgen receptor (AR) is a hallmark of this incurable cancer. Molecular changes during cancer enhance AR sensitivity or permit AR activation by antiestrogen so that pro…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Wang, Dasheng; Yang, Jian
- Licensing Officer: Taysavang, Panya
Novel Indole-3-Carbinol-Derived Antitumor Agents
TS-014815 — An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.
According to the Center for Disease Control and Prevention, cancer is the second leading cause of death in the US at approximately 600,000 deaths per year. In addition, the National Cancer Institute estimates that nearly 1.7 million cases of cancer are diagnosed each year. A report from U.S. News …
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Weng, Jing-ru
- Licensing Officer: Taysavang, Panya
Novel Protein Kinase C Delta Activators
TS-014754 — A novel anti-cancer agent (OSU-2S) that is devoid of S1P1 receptor activity and is highly effective in suppressing hepatocellular carcinoma tumor growth in vivo.
The third leading cause of cancer death worldwide is hepatocellular carcinoma (HCC). Due to the rise in the incidence of hepatitis C virus infection, HCC is expected to increase in the United States. Many patients with HCC are not candidates for surgery because of the location or size of their tum…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Byrd, John; Kulp, Samuel; Muthusamy, Natarajan; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
Glucose Transporter Inhibitors (GLUT1 Inhibitors)
TS-014734 — A potential cancer treatment that suppresses the ability for cancer cells to intake glucose, thereby hampering cancer cell production.
A fundamental property of neoplastic cells is the shift in cellular metabolism from oxidative phosphorylation to aerobic glycolysis. This glycolytic shift, called the Warburg effect, enables cancer cells to adapt to low-oxygen microenvironments, to generate biosynthetic building blocks for cell pr…
- College: College of Pharmacy
- Inventors: Chen, Ching-Shih; Kulp, Samuel; Wang, Dasheng
- Licensing Officer: Taysavang, Panya
